Abecma® (idecabtagene vicleucel)
for Multiple Myeloma

Abecma (idecabtagene vicleucel) is a CAR T-cell therapy used to treat relapsed or refractory multiple myeloma in adults who have received at least two prior treatments, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody. It is a one-time, personalized infusion made from a patient’s own T cells, genetically modified to target BCMA on myeloma cells, helping the immune system attack and destroy cancer cells.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Multiple Myeloma